查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1834170

子宫内膜异位症治疗市场（依治疗类型、给药途径、最终用户和分销管道）—全球预测 2025-2032

Endometriosis Treatment Market by Treatment Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年子宫内膜异位症治疗市场将成长至 54.8 亿美元，复合年增长率为 7.58%。

主要市场统计数据
基准年2024年 30.5亿美元
预计2025年 32.8亿美元
预测年份：2032年 54.8亿美元
复合年增长率（%） 7.58%

全面介绍塑造现代子宫内膜异位症治疗生态系统的不断发展的临床方法、患者治疗路径和相关人员的优先事项

子宫内膜异位症是一种复杂的慢性妇科疾病，临床需求多样，治疗週期长。近年来，该领域在诊断方法、患者期望、治疗途径和治疗创新方面经历了巨大变化。这些变化要求临床医生、付款方、製造商和护理提供者重新评估既定的常规治疗方案，并适应及时诊断、个人化管理和整体患者支持至关重要的环境。

引言部分将读者置于临床实务与医疗保健系统动态的交会点。它整合了当代挑战，包括延迟诊断、外科和内科管理的差异以及患者报告结果日益增长的重要性。它还强调了变革的驱动因素，包括技术支援的诊断、新型药理机制以及不断变化的报销压力。透过从临床、营运和商业性角度探讨这个主题，它提出了对策略重点、相关人员权衡和实施障碍的预期，这些将在后续章节中进行探讨。

总之，本介绍观点旨在让决策者对当前情况有一个简明的了解，并强调为什么结合临床证据、供应连续性和以患者为中心的服务的整合策略对于改善长期结果和业务绩效至关重要。

研究正在重塑子宫内膜异位症诊断途径、护理模式和治疗方法方案的快速临床、技术和患者变化

在临床进展、技术应用、支付方调整以及患者群体参与度提升的共同影响下，子宫内膜异位症的治疗格局正在改变。临床上，人们更重视早期发现和多学科干预，包括荷尔蒙管理、疼痛管理和微创手术（如有指征）。同时，诊断辅助工具和数位化分流工具也开始缩短专科医师就诊时间，重塑病患就诊的地点和时间。

在商业和营运方面，製造商和医疗保健提供者正在适应更差异化的治疗组合和不断变化的报销环境。付款人和医疗保健系统正在优先考虑那些能够显着降低下游资源利用率并改善生活品质的干预措施，从而推动对比较有效性和真实世界证据的审查。病患权益倡议和共用决策也在重新定义价值架构。患者在评估治疗方法方案时，越来越重视症状控制、生育能力保留以及对生活品质的影响。

综上所述，这些变化迫使相关人员重新评估其产品开发策略、供应商教育和医疗准入倡议。成功的相关人员将把临床证据的产生与切合实际的实施计划相结合，这些计划将考虑到不断变化的诊断工作流程、多样化的医疗环境以及对以患者为中心的治疗结果日益增长的期望。

分析 2025 年美国关税及其对供应链、筹资策略和患者获得子宫内膜异位症治疗的连锁影响

关税变化等政策槓桿可能会对药品和器械供应链产生连锁反应，子宫内膜异位症治疗领域的相关人员应密切关注美国宣布的2025年关税。这些关税可能会影响子宫内膜异位症治疗的原料药、成品药和手术耗材的采购。这些动态可能会增加依赖进口的供应链的管理复杂性，并鼓励区域筹资策略。

营运团队必须预测进口成本的增加将如何影响库存策略、合约订购和战略储备。采购团队可以透过寻求多元化的供应商网络、协商长期合约或转向大规模整合采购来应对波动。同时，製造商可以考虑本地生产或委託加工协议，以保持竞争性价格并最大限度地减少分销摩擦。

从病人取得医疗服务的角度来看，关税造成的中断可能会重塑分销管道和医疗机构的采购模式。实施临时缓解措施，例如预购协议、一体化物流以及医疗机构网路之间的联合采购，可以减轻短期影响。最终，积极评估供应链风险并调整筹资策略的相关人员将最有能力维持不间断的医疗服务，并为病患保留治疗选择。

对子宫内膜异位症治疗细分、ROA、治疗前景和分销管道的洞察将有助于确定子宫内膜异位症的临床优先顺序和服务提供

有意义的细分可以揭示临床需求的分歧点以及可以应用操作槓桿的领域。依治疗类型划分，子宫内膜异位症的治疗涵盖补充疗法、荷尔蒙疗法、疼痛管理和手术治疗。荷尔蒙疗法类别包括Aromatase抑制剂、促性腺激素释放激素促效剂、促性腺激素释放激素拮抗剂、口服避孕药和黄体素，每种疗法的疗效、耐受性考虑和监测需求各不相同。疼痛管理策略包括使用非类固醇消炎剂)和鸦片类药物，其中非类固醇消炎剂包括双氯芬酸钠、Ibuprofen和萘普生，鸦片类药物包括可待因和氢可酮衍生物。

给药途径是另一个关键的区分因素，注射剂、口服剂和外用剂会影响依从性动态、就诊频率和供应物流。门诊手术中心、医院和专科诊所必须分别考虑不同的手术能力、手术全期方案和影响治疗顺序的患者吞吐量。分销管道完善了细分格局，因为医院、线上和零售药局的途径会影响库存管理、患者获取时间表和治疗咨询机会。

整合这些层面，使相关人员能够确定临床教育、製剂设计和目标服务模式的介入点。能够反映治疗层级、给药途径、护理环境和分销管道之间相互作用的策略决策，能够更有效地满足患者的不同需求，并简化营运执行。

对子宫内膜异位症的临床实践、报销框架和患者可近性进行区域分析，比较美洲、欧洲、中东和非洲地区以及亚太地区的情况

区域动态对子宫内膜异位症治疗的提供和取得方式有着显着的影响，各主要地区的实践模式、法规环境和付款人政策有显着差异。美洲地区通常由私人和公共付款人组成，加护治疗中心和微创手术技术的采用率有所提高，而新药选择的可及性则因付款人政策和区域供应商关係而异。相较之下，欧洲、中东和非洲的国家医疗保健系统、监管时间表和报销规则各不相同，导致新治疗方法的采用率和对保留生育能力方法的重视程度各不相同。

亚太市场更加多元化，一些国家优先考虑快速采用创新诊断和护理途径，以实现远端医疗，而另一些国家则因供应链复杂性和报销优先顺序不同而面临准入限制。此外，从医院药房网路到蓬勃发展的线上药局服务的分销管道的成熟度，将决定患者获得急性治疗和维持治疗的可及性。

了解这些区域差异将有助于更好地分配资源、基于本地的证据产生以及製定具有商业性可行性的可近性策略。相关人员应根据当地监管要求和患者可近性实际情况，调整临床支援、定价策略和供应模式，以优化疗效并实现永续性。

子宫内膜异位症生态系统中的公司正在寻求各种策略布局，这些策略将影响创新步伐和市场动态。现有的治疗公司持续优化现有产品组合，选择性地推进下一代荷尔蒙药物以及针对疼痛和疾病进展的新机制。同时，规模较小的生物製药和医疗设备公司则专注于利基适应症、辅助性治疗和诊断技术，以缩短诊断时间并制定个人化治疗方法方案。

在整个竞争格局中，授权合约、共同开发和商业合作等伙伴关係模式对于加速药物取得和共用开发风险变得越来越重要。策略定位也延伸到真实世界证据产生和患者参与专案的能力，这些能力会影响付款人谈判和临床医生的采用。投资于可证明的疗效、精简的製造地和弹性供应链的公司可以降低采用障碍，并与付款人和医疗保健提供者建立更牢固的关係。

最终，企业在研发优先事项、商业模式和生态系统伙伴关係关係方面的策略选择将决定哪些公司能够最有效地扩大其创新规模。那些将临床证据与切合实际的部署策略和强大的患者支持系统相结合的公司，将最有可能在整个病人历程旅程中产生可持续的影响。

为领导者提供切实可行的建议，以加速诊断、改善治疗途径、增强供应弹性并改善子宫内膜异位症患者照护

透过采取优先且可操作的步骤，可以加速子宫内膜异位症治疗的显着改善。首先，投资临床医生和基层医疗的教育，以减少诊断延误，并确保持续使用以指南为导向的出版途径。其次，透过强调现实世界结果、生活品质指标和比较有效性，使证据产生策略与付款方优先事项保持一致，以支持将其纳入医疗覆盖范围的讨论和製定中。

第三，我们正在透过多元化供应商、探索区域製造方案以及实施策略性库存实践来增强供应链的韧性，以缓解关税和物流中断的影响。第四，我们正在设计以患者为中心的服务模式，整合药物管理、疼痛控制策略、不孕症咨询和心理社会支持，以满足不孕症患者的多方面需求。第五，我们正在利用数位工具来促进远端监控、依从性支持和分诊，减少不必要的就诊，并提高护理的连续性。

更精准的诊断和个人化治疗能够改善治疗效果，从而支持付款方的价值，并为持续创新提供稳定的收入来源。领导者应优先考虑那些能带来可衡量临床效益，同时又能在现有医疗基础设施内运作的干预措施。

清晰说明研究框架、资料收集和检验过程以及用于深入了解子宫内膜异位症护理的分析方法。

本研究采用结构化、多源方法，确保研究结果的稳健性和可靠性。主要的定性输入包括对临床医生、采购专业人员和患者权益倡导者的深入访谈，并辅以对同行评审的临床研究、监管指南和实践指南的二次资讯来源回顾。对这些输入进行三角检验，以检验主题研究观察，并识别临床实践和营运决策中的一致模式。

此分析方法结合了定性综合分析、基于情境的供应链映射和相关人员影响分析。检验方案包括将访谈结果与公开的监管文件和程序标准进行交叉引用，并对医疗保健提供途径的假设进行敏感性检验。研究尽可能强调证据来源与结论之间的透明度，以便使用者追踪特定见解的形成过程。

调查方法优先考虑可重复性、清晰的假设和情境解读，而非预测量化。资料来源、访谈架构和分析逻辑均清楚记录，以支援临床医生、商业团队和采购专业人员根据自身营运进行后续应用。

设定相关人员的优先事项，以改善子宫内膜异位症的诊断、护理服务和病患结果

总结总结汇集了临床、营运和商业视角，旨在明确策略重点。诊断延迟、治疗方案采用不均衡以及供应链漏洞是影响病患体验和系统绩效的持续性问题。为此，将临床医生教育、证据生成、弹性采购和以患者为中心的服务设计相结合的协作策略，是实现持久改进的最有希望的途径。

相关人员应优先考虑能够带来切实临床益处的干预措施，同时解决影响可及性和依从性的后勤限制。例如，加强专家早期发表的途径，使治疗价值主张与付款方证据提案保持一致，以及投资于供应链冗余以降低治疗中断的风险。重要的是，将患者的声音纳入研究和服务设计中，将透过展示生活品质的改善来提高相关性并加速应用。

摘要：取得进展需要多学科合作和切实可行的实施。将科学创新与实际操作现实和患者需求相结合，可以显着改善子宫内膜异位症患者的医疗服务和预后。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 采用口服 GnRH 拮抗剂可促进个人化治疗通讯协定，并减少副作用
  • 整合数位健康平台，用于子宫内膜异位症管理中的远端监控和症状跟踪
  • 针对减少子宫内膜病变的选择性雌激素受体调节的临床试验正在增加
  • 扩大微创机器人辅助手术，改善病患復原和生育能力
  • 旨在减少慢性子宫内膜异位症发炎的生技药品和免疫调节疗法的增长
  • 增加对生物标记研究的投资，用于早期非侵入性诊断和监测疾病进展
  • 製药和诊断公司合作开发荷尔蒙疗法的伴随诊断测试
  • 开发一种植入缓释性药物输送系统，用于持续缓解子宫内膜异位症症状

第六章 2025年美国关税的累积影响

第七章 人工智慧的累积影响，2025年

第八章子宫内膜异位症治疗市场（依治疗类型）

  • 补充疗法
  • 荷尔蒙疗法
    • Aromatase抑制剂
    • GnRH促效剂
    • Gnrh拮抗剂
    • 口服避孕药
    • 黄体素
  • 疼痛管理
    • NSAIDs
      • 双氯芬酸钠
      • Ibuprofen
      • 萘普生
    • 阿片类药物
      • 可待因
      • 氢可酮
  • 手术治疗

9. 子宫内膜异位症治疗市场（依给药途径）

  • 注射
  • 口服
  • 局部的

第 10 章子宫内膜异位症治疗市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第11章子宫内膜异位症治疗市场依通路划分

  • 医院药房
  • 网路药局
  • 零售药局

第十二章子宫内膜异位症治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章子宫内膜异位症治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 子宫内膜异位症治疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AbbVie Inc.
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd
    • Ferring International Center SA
    • Mylan NV
    • Sandoz International GmbH
    • Lupin Limited
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Dr. Reddy's Laboratories Ltd.
Product Code: MRR-4348D129FA88

The Endometriosis Treatment Market is projected to grow by USD 5.48 billion at a CAGR of 7.58% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.05 billion
Estimated Year [2025] USD 3.28 billion
Forecast Year [2032] USD 5.48 billion
CAGR (%) 7.58%

Comprehensive introduction to evolving clinical approaches, patient pathways, and stakeholder priorities shaping modern endometriosis treatment ecosystems

Endometriosis is a complex, chronic gynecologic condition that drives diverse clinical needs and long trajectories of care. Over recent years, the field has experienced substantive changes in diagnostic approaches, patient expectations, care delivery pathways, and therapeutic innovation. These shifts require clinicians, payers, manufacturers, and care providers to reassess established routines and adapt to an environment where timely diagnosis, individualized management, and holistic patient support are paramount.

The introduction situates readers at the intersection of clinical practice and health system dynamics. It synthesizes contemporary challenges such as diagnostic delays, variability in surgical and medical management, and the increasing prominence of patient-reported outcomes. It also highlights the drivers of change, including technology-enabled diagnostics, new pharmacologic mechanisms, and evolving reimbursement pressures. By framing the topic across clinical, operational, and commercial dimensions, the narrative sets expectations for strategic priorities, stakeholder trade-offs, and implementation barriers that will be explored in subsequent sections.

In sum, this introductory perspective aims to equip decision-makers with a concise orientation to the current landscape, clarifying why integrated strategies that bridge clinical evidence, supply continuity, and patient-centered services are essential to improving long-term outcomes and operational performance.

Examination of rapid clinical, technological, and patient shifts reshaping diagnostic pathways, care delivery models and therapeutic choices in endometriosis care

The landscape of endometriosis treatment is shifting under the combined influence of clinical advances, technology diffusion, payer recalibration, and more engaged patient communities. Clinically, there is a clearer emphasis on earlier recognition and on integrating multimodal interventions that combine hormonal management, pain control, and minimally invasive surgery when indicated. Concurrently, diagnostic adjuncts and digital triage tools are starting to reduce time to specialist referral, reshaping where and when patients enter care pathways.

On the commercial and operational side, manufacturers and providers are adapting to more differentiated therapeutic portfolios and variable reimbursement environments. Payers and health systems are prioritizing interventions that demonstrably reduce downstream resource utilization and improve quality of life, prompting deeper scrutiny of comparative effectiveness and real-world evidence. Patient advocacy and shared decision-making are also redefining value frameworks: patients increasingly weigh symptom control, fertility preservation, and quality-of-life impacts when evaluating therapy options.

Taken together, these transformative shifts compel stakeholders to reevaluate product development strategies, provider education, and access initiatives. Successful actors will align clinical evidence generation with pragmatic implementation plans that account for evolving diagnostic workflows, heterogeneous care settings, and rising expectations for patient-centered outcomes.

Analysis of US tariff measures in 2025 and their cascading effects on supply chains, procurement strategies, and patient access to endometriosis therapies

Policy levers such as tariff changes can ripple through pharmaceutical and device supply chains, and the announced United States tariff measures for 2025 warrant careful attention from stakeholders involved in endometriosis care. Tariff-driven cost pressures may alter supplier selection and procurement practices, with implications for sourcing of active pharmaceutical ingredients, finished medicines, and surgical consumables used in endometriosis management. These dynamics can raise the administrative complexity of import-dependent supply lines and incentivize regional sourcing strategies.

Operational teams must anticipate how increased import costs could influence inventory policy, contracting cadence, and strategic stockpiles. Procurement groups may respond by seeking diversified supplier networks, negotiating longer-term agreements, or shifting toward larger consolidated purchases to mitigate volatility. Providers and specialty clinics should evaluate formulary implications as product economics change; meanwhile, manufacturers may consider localized manufacturing or tolling arrangements to preserve competitive pricing and minimize distribution friction.

From a patient access perspective, tariff-induced disruptions can reshape availability patterns across distribution channels and care settings. Transitional mitigation measures, such as advance purchase agreements, consolidated logistics, and collaborative sourcing among provider networks, can attenuate short-term impacts. Ultimately, stakeholders that proactively assess supply chain exposures and adapt procurement strategies will be better positioned to sustain uninterrupted care and preserve therapeutic choice for patients.

Insights into treatment segments, ROA, care settings, and distribution pathways that inform clinical priorities and service delivery for endometriosis

Meaningful segmentation illuminates where clinical needs diverge and where operational levers can be applied. When viewed through treatment type, endometriosis management spans Complementary Therapies, Hormonal Therapies, Pain Management, and Surgical Treatment. Hormonal Therapies encompass classes such as Aromatase Inhibitors, GnRH Agonists, GnRH Antagonists, Oral Contraceptives, and Progestins, each carrying distinct efficacy profiles, tolerability considerations, and monitoring needs. Pain Management strategies include the use of NSAIDs and Opioids, and the NSAID category itself is commonly represented by agents such as Diclofenac, Ibuprofen, and Naproxen, while opioid options frequently involve codeine and morphine derivatives; these choices implicate different safety monitoring and prescribing frameworks.

Route of administration is another critical differentiator, with injectable, oral, and topical modalities shaping adherence dynamics, clinic visit frequency, and supply logistics. End user settings also matter materially: ambulatory surgical centers, hospitals, and specialty clinics each offer different procedural capabilities, perioperative protocols, and patient throughput considerations that affect treatment sequencing. Distribution channels complete the segmentation picture, as hospital pharmacy, online pharmacy, and retail pharmacy pathways influence inventory management, patient access timelines, and opportunities for therapeutic counseling.

By synthesizing these layers, stakeholders can identify intervention points for clinical education, formulary design, and targeted service models. Strategic decisions that reflect the interplay between therapeutic class, administration route, care setting, and distribution pathway will more effectively meet heterogeneous patient needs and streamline operational execution.

Regional analysis of clinical practice, reimbursement frameworks, and patient access that contrasts the Americas, EMEA, and Asia-Pacific landscapes in endometriosis

Regional dynamics exert a strong influence on how endometriosis care is delivered and accessed, with meaningful variation in practice patterns, regulatory environments, and payer policies across major geographies. The Americas tend to reflect a mix of private and public payer arrangements, with centralized centers of excellence and growing adoption of minimally invasive surgical techniques, while access to new pharmacologic options varies according to payer policy and regional supplier relationships. By contrast, Europe, the Middle East & Africa display a heterogeneous mosaic of national healthcare systems, regulatory timelines, and reimbursement rules, leading to varied adoption rates for novel therapies and differing emphases on fertility-preserving approaches.

Asia-Pacific markets present additional diversity: some jurisdictions prioritize rapid adoption of innovative diagnostics and telehealth-enabled care pathways, while others face access constraints driven by supply chain complexity and differing reimbursement priorities. Across regions, the balance between hospital-centric procedures and ambulatory care alternatives affects where patients receive surgery and follow-up, and distribution channel maturity-from hospital pharmacy networks to rapidly growing online pharmacy services-shapes patient access to both acute and maintenance therapies.

Understanding these regional contrasts enables more precise allocation of resources, localized evidence generation, and commercially realistic access strategies. Stakeholders should tailor clinical support, pricing strategies, and supply models to regional regulatory imperatives and patient access realities to optimize outcomes and sustainability.

Companies operating in the endometriosis ecosystem are pursuing a range of strategic plays that impact innovation velocity and market dynamics. Established therapeutics manufacturers continue to optimize existing portfolios while selectively advancing next-generation hormonal agents and novel mechanisms that target pain and lesion progression. At the same time, smaller biopharma and device innovators focus on niche indications, adjunctive therapies, and technology-enabled diagnostics designed to improve time to diagnosis and personalize treatment selection.

Across the competitive landscape, partnership models-such as licensing agreements, co-development collaborations, and distribution alliances-are increasingly important for accelerating access and sharing developmental risk. Strategic positioning also extends to capabilities in real-world evidence generation and patient engagement programs, which influence payer negotiations and clinician adoption. Firms that invest in demonstrable outcomes, streamlined manufacturing footprints, and resilient supply chains will reduce barriers to adoption and build stronger payer and provider relationships.

Ultimately, corporate strategic choices around R&D prioritization, commercial models, and ecosystem partnerships will determine who can scale innovations most effectively. Companies that integrate clinical evidence with pragmatic deployment strategies and robust patient support systems will emerge best positioned to deliver sustainable impact across the patient journey.

Actionable recommendations for leaders to expedite diagnosis, refine therapeutic pathways, strengthen supply resilience, and elevate patient care in endometriosis

Actionable, prioritized steps can help organizations accelerate meaningful improvements in endometriosis care. First, invest in clinician and primary care education to reduce diagnostic delays and ensure consistent use of guideline-based referral pathways; earlier identification streamlines care and expands therapeutic options. Second, align evidence-generation strategies with payer priorities by emphasizing real-world outcomes, quality-of-life metrics, and comparative effectiveness to support coverage discussions and formulary inclusion.

Third, strengthen supply chain resilience by diversifying suppliers, exploring regional manufacturing options, and implementing strategic inventory practices to mitigate tariff or logistics disruptions. Fourth, design patient-centered service models that integrate pharmacologic management, pain control strategies, fertility counseling, and psychosocial support to address the multifaceted needs of individuals living with the condition. Fifth, leverage digital tools to facilitate remote monitoring, adherence support, and triage, thereby reducing unnecessary visits and enhancing continuity of care.

When implemented cohesively, these recommendations create a reinforcing cycle: better diagnosis and tailored therapies improve outcomes, which in turn support payer value arguments and stabilize revenue streams necessary for continued innovation. Leaders should prioritize interventions that deliver measurable clinical benefit while remaining operationally feasible within existing care infrastructures.

Clear description of research framework, data collection and validation processes, and analytical methods applied to derive insights on endometriosis care

This research applied a structured, multi-source approach to ensure the robustness and credibility of findings. Primary qualitative inputs included in-depth interviews with clinicians, procurement specialists, and patient advocates, complemented by secondary literature reviews of peer-reviewed clinical studies, regulatory guidances, and practice guidelines. Triangulation across these inputs was used to validate thematic findings and identify consistent patterns across clinical practice and operational decision-making.

Analytical methods combined qualitative synthesis with scenario-based supply chain mapping and stakeholder impact analysis. Validation protocols included cross-checking interview insights with publicly available regulatory documents and procedural standards, and applying sensitivity checks to assumptions about care delivery pathways. Wherever possible, the research emphasized transparent linkage between evidence sources and derived conclusions, enabling users to trace how specific insights were developed.

The methodology prioritized reproducibility, clarity of assumptions, and contextual interpretation rather than predictive quantification. Clear documentation of data sources, interview frameworks, and analytic logic supports downstream application by clinicians, commercial teams, and procurement professionals seeking to adapt the insights to their own operational contexts.

Concluding synthesis of key findings and implications setting priorities for stakeholders to improve diagnosis, care delivery, and patient outcomes in endometriosis

The concluding synthesis brings together clinical, operational, and commercial perspectives to clarify strategic priorities. Delays in diagnosis, heterogeneous adoption of therapeutic options, and supply chain vulnerabilities emerge as persistent themes that shape patient experience and system performance. In response, coordinated strategies that combine clinician education, evidence generation, resilient procurement, and patient-focused service design provide the most promising avenue for durable improvement.

Stakeholders should prioritize interventions that deliver tangible clinical benefit while also addressing logistical constraints that influence access and adherence. Examples include bolstering pathways for early specialist referral, aligning therapeutic value propositions with payer evidence needs, and investing in supply chain redundancies that reduce the risk of therapeutic interruptions. Importantly, integrating patient voice into research and service design amplifies relevance and can accelerate uptake through demonstrable improvements in quality of life.

In summary, the path forward requires multidisciplinary collaboration and pragmatic implementation. By aligning scientific innovation with operational realism and patient priorities, the sector can advance meaningful improvements in care delivery and outcomes for people affected by endometriosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of oral GnRH antagonists driving personalized treatment protocols with reduced side effects
  • 5.2. Integration of digital health platforms for remote monitoring and symptom tracking in endometriosis management
  • 5.3. Increasing clinical trials exploring selective estrogen receptor modulators for targeted endometrial lesion reduction
  • 5.4. Expansion of minimally invasive robotic-assisted surgeries to improve patient recovery and fertility outcomes
  • 5.5. Growth of biologics and immunomodulatory therapies aimed at inflammation control in chronic endometriosis cases
  • 5.6. Rising investment in biomarker research for early noninvasive diagnosis and disease progression monitoring
  • 5.7. Collaborations between pharmaceutical and diagnostic companies to develop companion diagnostic tests for hormone therapies
  • 5.8. Development of implantable extended-release drug delivery systems for sustained endometriosis symptom relief

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endometriosis Treatment Market, by Treatment Type

  • 8.1. Complementary Therapies
  • 8.2. Hormonal Therapies
    • 8.2.1. Aromatase Inhibitors
    • 8.2.2. Gnrh Agonists
    • 8.2.3. Gnrh Antagonists
    • 8.2.4. Oral Contraceptives
    • 8.2.5. Progestins
  • 8.3. Pain Management
    • 8.3.1. Nsaids
      • 8.3.1.1. Diclofenac
      • 8.3.1.2. Ibuprofen
      • 8.3.1.3. Naproxen
    • 8.3.2. Opioids
      • 8.3.2.1. Codeine
      • 8.3.2.2. Morphine
  • 8.4. Surgical Treatment

9. Endometriosis Treatment Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Endometriosis Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Endometriosis Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Endometriosis Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endometriosis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endometriosis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. Bayer AG
    • 15.3.3. Teva Pharmaceutical Industries Ltd
    • 15.3.4. Ferring International Center S.A.
    • 15.3.5. Mylan N.V.
    • 15.3.6. Sandoz International GmbH
    • 15.3.7. Lupin Limited
    • 15.3.8. Pfizer Inc.
    • 15.3.9. Sun Pharmaceutical Industries Ltd
    • 15.3.10. Dr. Reddy's Laboratories Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ENDOMETRIOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ENDOMETRIOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENDOMETRIOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER